References
- Addy C, Tatosian D, Glasgow XS, et al. (2016). Pharmacokinetic and pharmacodynamic effects of multiple-dose administration of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in obese participants with and without Type 2 diabetes mellitus. Clin Ther 38:516–30.
- Biftu T, Sinha-Roy R, Chen P, et al. (2014). Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem 57:3205–12.
- Burness CB. (2015). Omarigliptin: first global approval. Drugs 16:1947–52.
- Drucker DJ. (2006). The biology of incretin hormones. Cell Metab 3:153–65.
- Dueker SR, Lohstroh PN, Giacomo JA, et al. (2010). Early human ADME using microdoses and microtracers: bioanalytical considerations. Bioanalysis 2:441–54.
- Fagerholm U. (2007). Prediction of human pharmacokinetics – renal metabolic and excretion clearance. J Pharm Pharmacol 59:1463–71.
- Fuchs H, Tillement JP, Urien S, et al. (2009). Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol 61:55–62.
- Holst JJ, Vilsboll T, Deacon CF. (2009). The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297:127–36.
- Hop CE, Wang Z, Chen Q, et al. (1998). Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901–3.
- IDF Diabetes Atlas, 7th ed. (2015). International Diabetes Federation: Brussels, Belgium; http://www.idf.org
- Krishna R, Addy C, Tatosian D, et al. (2016). Pharmacokinetics and pharmacodynamics of omarigliptin, a once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, after single and multiple doses in healthy subjects. J Clin Pharmacol 56:1528–37.
- Mentlein R. (1999). Dipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptides. Regul Pept 85:9–24.
- Nauck MA, Meininger G, Sheng D, et al. (2007). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 9:194–205.
- R Core Team (2016). R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. URL https://doi.org/https://www.R-project.org/
- Ren S, Gauthier D, Marques R, et al. (2016). Synthesis of [(14) C]omarigliptin. J Labelled Comp Radiopharm 59:386–90.
- Roffey SJ, Obach RS, Gedge JI, et al. (2007). What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39:17–43.
- Rowland M, Tozer T. (2004). Clinical pharmacokinetics concepts and applications. 3rd ed. Philadelphia: Lippincott William & Wikins. 173 p.
- Sheu WH, Gantz I, Chen M, et al. (2015). Safety and efficacy of omarigliptin (MK-3102), a novel once-weekly DPP-4 inhibitor for the treatment of patients with type 2 diabetes. Diabetes Care 38:2106–14.
- Tsuchiya S, Friedman E, Addy C, et al. (2017). Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men. J Diabetes Investig 8:84–92.
- Young GC, Seymour M. (2015). Application of (14)C-accelerator MS in pharmaceutical development. Bioanalysis 7:513–17.
- Xu L, Man CD, Charbonnel B, et al. (2008). Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 10:1212–20.